Randomized, Single-dose, Parallel-arm, Open-label Phase I Trial to Investigate and Compare the Pharmacokinetics, Safety and Tolerability of BI 695501 Administered Subcutaneously Via Prefilled Syringe or Autoinjector
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 08 Nov 2016 Status changed from active, no longer recruiting to completed.
- 02 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.